These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24328466)

  • 1. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting.
    Schiffman M; Solomon D
    N Engl J Med; 2013 Dec; 369(24):2324-31. PubMed ID: 24328466
    [No Abstract]   [Full Text] [Related]  

  • 2. Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap.
    Dinkelspiel H; Fetterman B; Poitras N; Kinney W; Cox JT; Lorey T; Castle PE
    J Low Genit Tract Dis; 2014 Jan; 18(1):57-60. PubMed ID: 24022057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rationale for implementation of HPV testing in routine cervical screening in Romania.
    Iancu LS; Ursu RG
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):293-6. PubMed ID: 24340506
    [No Abstract]   [Full Text] [Related]  

  • 4. Screening Guideline for Cervical Cancer Recommends Against Human Papillomavirus-Pap Cotesting.
    Azvolinsky A
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29155972
    [No Abstract]   [Full Text] [Related]  

  • 5. Human papillomavirus DNA and Pap tests: the need for cotesting in opportunistic setting during the transition time.
    Mariani L; Sideri M; Costa S; Cristoforoni P; Origoni M; Preti M;
    J Low Genit Tract Dis; 2013 Jul; 17(3):362-5. PubMed ID: 23552207
    [No Abstract]   [Full Text] [Related]  

  • 6. Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia.
    Zhao C; Li Z; Austin RM
    Am J Clin Pathol; 2013 Jul; 140(1):47-54. PubMed ID: 23765533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
    Sawaya GF
    Arch Intern Med; 2010 Jun; 170(11):985-6. PubMed ID: 20548012
    [No Abstract]   [Full Text] [Related]  

  • 8. Could urine testing be the future of cervical cancer screening?
    Pathak N; Dodds J; Zamora J
    Womens Health (Lond); 2015 Jun; 11(3):265-7. PubMed ID: 26102464
    [No Abstract]   [Full Text] [Related]  

  • 9. Adding a test for human papillomavirus DNA to cervical-cancer screening.
    Wright TC; Schiffman M
    N Engl J Med; 2003 Feb; 348(6):489-90. PubMed ID: 12571255
    [No Abstract]   [Full Text] [Related]  

  • 10. Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.
    Nishino HT; Tambouret RH; Wilbur DC
    Cancer Cytopathol; 2011 Aug; 119(4):219-27. PubMed ID: 21717588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2013 statement on human papillomavirus test utilization [corrected].
    Davis Davey D; Goulart R; Nayar R;
    Diagn Cytopathol; 2014 May; 42(5):449-52. PubMed ID: 24700624
    [No Abstract]   [Full Text] [Related]  

  • 12. The latest recommendations from the USPSTF.
    Campos-Outcalt D
    J Fam Pract; 2012 May; 61(5):278-82. PubMed ID: 22577630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?
    Saraiya M; Berkowitz Z; Yabroff KR; Wideroff L; Kobrin S; Benard V
    Arch Intern Med; 2010 Jun; 170(11):977-85. PubMed ID: 20548011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HPV-tests as suitable complement to cytological screening].
    Rubinstein E
    Lakartidningen; 1999 May; 96(18):2195. PubMed ID: 10377654
    [No Abstract]   [Full Text] [Related]  

  • 15. Patient safety and the next generation of HPV DNA tests.
    Lee SH
    Am J Clin Pathol; 2011 Mar; 135(3):481; author reply 482-3. PubMed ID: 21350106
    [No Abstract]   [Full Text] [Related]  

  • 16. Human papillomavirus testing for primary cervical cancer screening: is it time to abandon Papanicolaou testing?
    Feldman S
    JAMA Intern Med; 2014 Oct; 174(10):1539-40. PubMed ID: 25069413
    [No Abstract]   [Full Text] [Related]  

  • 17. Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial.
    Smith L; van Niekerk D; Coldman A; Krajden M; Franco EL; Ogilvie G
    J Obstet Gynaecol Can; 2016 Aug; 38(8):723-6. PubMed ID: 27638983
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cervical cancer screening: restoration or reconstruction?].
    Riethmuller D
    Gynecol Obstet Fertil; 2009; 37(7-8):671-9. PubMed ID: 19577501
    [No Abstract]   [Full Text] [Related]  

  • 19. Exhortations to abandon the Pap test as a routine initial cervical screening test are still premature and carry significant risks.
    Austin RM
    Diagn Cytopathol; 2010 Nov; 38(11):783-7. PubMed ID: 20607804
    [No Abstract]   [Full Text] [Related]  

  • 20. 2013 statement on human papillomavirus [corrected] test utilization.
    Davis Davey D; Goulart R; Nayar R;
    Acta Cytol; 2014; 58(2):113-6. PubMed ID: 24525558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.